大缺血性卒中血管内取栓:缺血损伤与半暗带特征分析
该研究为SELECT2随机临床试验的探索性分析,纳入352例因颈内动脉或大脑中动脉M1段闭塞且大缺血核心的急性缺血性卒中成人(18-85岁),随机接受血管内取栓(EVT)或药物管理(MM),覆盖31个全球中心(2019年10月至2022年9月)。主要终点为90天改良Rankin量表(mRS)评分,采用调整广义比值比(aGenOR)评估。结果显示,EVT在ASPECTS 3、4、5分层及CT灌注/MRI核心体积≥70 mL时改善功能结局,但在≥100 mL和≥150 mL时置信区间跨1;EVT组内,ASPECTS每降低1分或核心体积每增加10 mL,结局变差。结论认为EVT在广泛梗死体积谱中改善结局,但极小半暗带患者入组较少。
要点
- SELECT2探索性分析中,EVT组90天mRS在ASPECTS 3(aGenOR 1.71,95%CI 1.04-2.81)、4(2.01,1.19-3.40)、5(1.85,1.22-2.79)均优于MM。
- CT灌注/MRI核心体积≥70 mL时EVT优于MM(aGenOR 1.63,95%CI 1.23-2.16);≥100 mL(1.41,0.99-2.02)和≥150 mL(1.47,0.84-2.56)未达统计学显著。
- EVT组内,ASPECTS每降低1分结局变差(aGenOR 0.91,95%CI 0.82-1.00),核心体积每增加10 mL结局变差(aGenOR 0.92,95%CI 0.89-0.95)。
- 有无不匹配时未观察到EVT治疗效应异质性,但无匹配患者入组较少。
适用人群与场景
- 18-85岁急性缺血性卒中成人,因颈内动脉或大脑中动脉M1段闭塞且大缺血核心,来自31个全球中心,2019年10月至2022年9月随机入组。
诊断标准与关键阈值
- 缺血损伤程度由非增强CT的ASPECTS评分及CT灌注或MRI的核心体积(严重低灌注区或弥散受限)定义。
- ASPECTS分层包括3、4、5;核心体积分层包括≥70 mL、≥100 mL、≥150 mL。
处置流程与药物剂量
- 干预为血管内取栓(EVT)对比药物管理(MM)。
研究设计与关键结果
- 研究类型为SELECT2随机临床试验的探索性分析;352例随机,336例分析(中位年龄67岁;139例[41.4%]女性);168例(50%)随机至EVT,另2例交叉MM患者接受EVT。
- 90天mRS序贯分析:EVT vs MM在ASPECTS 3的aGenOR 1.71(95%CI 1.04-2.81),ASPECTS 4的aGenOR 2.01(95%CI 1.19-3.40),ASPECTS 5的aGenOR 1.85(95%CI 1.22-2.79)。
- CT灌注/MRI核心体积分层:≥70 mL的aGenOR 1.63(95%CI 1.23-2.16),≥100 mL的aGenOR 1.41(95%CI 0.99-2.02),≥150 mL的aGenOR 1.47(95%CI 0.84-2.56)。
- EVT组内:ASPECTS每降低1分,aGenOR 0.91(95%CI 0.82-1.00);核心体积每增加10 mL,aGenOR 0.92(95%CI 0.89-0.95)。
- 有无不匹配时未观察到EVT治疗效应异质性,但无匹配患者入组较少。
证据类型、等级与局限
- 证据类型:随机临床试验的探索性分析。
- 局限:原文报告为探索性分析;无匹配患者入组较少。
对床旁实践的改变
- 作者认为,在广泛梗死体积谱中EVT改善临床结局,但极小半暗带患者入组较少;EVT治疗患者中,就诊时缺血损伤估计越大结局越差。
指南或共识出处
- SELECT2试验(ClinicalTrials.gov Identifier: NCT03876457)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Whether endovascular thrombectomy (EVT) efficacy for patients with acute ischemic stroke and large cores varies depending on the extent of ischemic injury is uncertain.
OBJECTIVE: To describe the relationship between imaging estimates of irreversibly injured brain (core) and at-risk regions (mismatch) and clinical outcomes and EVT treatment effect.
DESIGN, SETTING, AND PARTICIPANTS: An exploratory analysis of the SELECT2 trial, which randomized 352 adults (18-85 years) with acute ischemic stroke due to occlusion of the internal carotid or middle cerebral artery (M1 segment) and large ischemic core to EVT vs medical management (MM), across 31 global centers between October 2019 and September 2022.
INTERVENTION: EVT vs MM.
MAIN OUTCOMES AND MEASURES: Primary outcome was functional outcome-90-day mRS score (0, no symptoms, to 6, death) assessed by adjusted generalized OR (aGenOR; values >1 represent more favorable outcomes). Benefit of EVT vs MM was assessed across levels of ischemic injury defined by noncontrast CT using ASPECTS score and by the volume of brain with severely reduced blood flow on CT perfusion or restricted diffusion on MRI.
RESULTS: Among 352 patients randomized, 336 were analyzed (median age, 67 years; 139 [41.4%] female); of these, 168 (50%) were randomized to EVT, and 2 additional crossover MM patients received EVT. In an ordinal analysis of mRS at 90 days, EVT improved functional outcomes compared with MM within ASPECTS categories of 3 (aGenOR, 1.71 [95% CI, 1.04-2.81]), 4 (aGenOR, 2.01 [95% CI, 1.19-3.40]), and 5 (aGenOR, 1.85 [95% CI, 1.22-2.79]). Across strata for CT perfusion/MRI ischemic core volumes, aGenOR for EVT vs MM was 1.63 (95% CI, 1.23-2.16) for volumes ≥70 mL, 1.41 (95% CI, 0.99-2.02) for ≥100 mL, and 1.47 (95% CI, 0.84-2.56) for ≥150 mL. In the EVT group, outcomes worsened as ASPECTS decreased (aGenOR, 0.91 [95% CI, 0.82-1.00] per 1-point decrease) and as CT perfusion/MRI ischemic core volume increased (aGenOR, 0.92 [95% CI, 0.89-0.95] per 10-mL increase). No heterogeneity of EVT treatment effect was observed with or without mismatch, although few patients without mismatch were enrolled.
CONCLUSION AND RELEVANCE: In this exploratory analysis of a randomized clinical trial of patients with extensive ischemic stroke, EVT improved clinical outcomes across a wide spectrum of infarct volumes, although enrollment of patients with minimal penumbra volume was low. In EVT-treated patients, clinical outcomes worsened as presenting ischemic injury estimates increased.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03876457.
参考来源
- Sarraj A, Hassan AE, Abraham MG, et al. Endovascular Thrombectomy for Large Ischemic Stroke Across Ischemic Injury and Penumbra Profiles. JAMA. 2024. PMID: 38324414. doi:10.1001/jama.2024.0572
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。